<DOC>
	<DOC>NCT01220076</DOC>
	<brief_summary>The biological response to treatment with tamoxifen in the preoperative situation is studying in this protocol. This study will enrolls patients with non-metastatic breast cancer HR +. The relationship between the CYP2D6 polymorphism, pharmacokinetics and biological efficacy of TAM will be studied.</brief_summary>
	<brief_title>Biological Response to Tamoxifen (TAM) in Patients With Breast Cancer Non Metastatic RH+</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>Adult Females (≥ 18 years), with effective contraception. The contraceptive should not use estrogen to a derivative. It must be continued during treatment with tamoxifen for at least two months after his arrest. histologically confirmed diagnosis of invasive breast cancer, previously untreated. Patients have been supported for a breast cancer may be included if a period of at least 2 years between the last systemic treatment of inclusion in the study. Primary tumor hormonopositive: ER and / or PR ≥ 50% by immunostaining with an HR for Allred score&gt; or = 3 lack of HER2 overexpression palpable primary tumor or greater than or equal to 20 mm in diameter, measured by ultrasound readily operable tumor No metastases Clinical Stage M0 performance index ≤ 1 (OMS) Polynuclear &gt; or = 1500 / mm3, Hb Platelets &gt; or = 100 000/mm3 Hb ≥10 g/dL normal liver function: bilirubin ≤ 1.5 x ULN, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x ULN (≤ 5 x ULN if liver metastases). Normal renal function (creatinine ≤ 1.5 mg / dL or creatinine clearance ≥ 60 mL / min) cardiac function (MUGA scan or ultrasound February&gt; 55%) and lung function, 5.2.2 Criteria related to participation in the study: Patient affiliated to social security, Patient has signed and dated consent Alcohol Consumption Pregnancy, Breastfeeding Smoking Use of St. John's Wort (herbal tea ...) within 5 days before starting treatment Consumption of grapefruit juice in the last 5 days of starting treatment congenital galactosemia malabsorption glucose and galactose lactase deficiency Comedications that may interfere with cytochrome P450: enzyme inducers in progress: Antiepileptic drugs: carbamazepine, phenobarbital, phenytoin Antinfectieux: rifampin, rifabutin, névrirapine, griséofilvine, efavirenz Enzyme Inhibitors in progress: Inhibitors of serotonin reuptake: fluoxetine, paroxetine Thioridazine. Quinidine Amiodarone Ca antagonists: diltiazem, verapamil azole antifungals ketoconazole, fluconazole, miconazole. No protease inhibitors: ritonavir, nelfinavir, amprenavir, indinavir. Macrolides: erythromycin, clarithromycin, josamycin</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Tamoxifen,</keyword>
	<keyword>Breat Cancer</keyword>
	<keyword>Pharmacogenetic</keyword>
	<keyword>non metastatic breast cancer, HR +</keyword>
</DOC>